#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1902	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2160	172.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1675	1675	T	224	T	141	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1902	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2160	172.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	197	C,A	135,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3906	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3870	194.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1859	1859	A	220	A	152	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3906	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3870	194.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2493	2493	C	207	C	129	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3906	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3870	194.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2567	2567	A	186	A	121	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3906	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3870	194.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3119	3119	C	242	C	160	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	180	folP	855	855	100.0	folP.l15.c4.ctg.1	1432	24.2	1	SNP	p	R229S	1	.	.	685	687	AGC	830	832	AGC	41;41;40	A;G;C	27;27;27	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	2751	99.93	gyrA.l6.c4.ctg.1	3340	26.2	0	.	p	.	0	G769fs	FSHIFT	2305	2305	G	2489	2489	G	6	G	2	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	2751	99.93	gyrA.l6.c4.ctg.1	3340	26.2	1	SNP	p	S91F	1	.	.	271	273	TTC	454	456	TTC	37;37;37	T;T;C	22;22;24	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	2751	99.93	gyrA.l6.c4.ctg.1	3340	26.2	1	SNP	p	D95G	1	.	.	283	285	GGC	466	468	GGC	37;38;38	G;G;C	25;23;22	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	2751	99.93	gyrA.l6.c4.ctg.1	3340	26.2	1	SNP	p	G95N	0	.	.	283	285	GGC	466	468	GGC	37;38;38	G;G;C	25;23;22	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	157	96.18	gyrA.l6.c4.ctg.2	494	0.0	0	.	p	.	0	M142L	NONSYN	424	426	ATG	36	38	CTG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	157	96.18	gyrA.l6.c4.ctg.2	494	0.0	0	.	p	.	0	I146L	NONSYN	436	438	ATT	48	50	CTT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	157	96.18	gyrA.l6.c4.ctg.2	494	0.0	0	.	p	.	0	L174P	NONSYN	520	522	CTG	132	134	CCG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	519	460	gyrA	2751	157	96.18	gyrA.l6.c4.ctg.2	494	0.0	0	.	p	.	0	G181R	NONSYN	541	543	GGT	153	155	CGT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	122	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1168	21.2	1	SNP	p	G45D	0	.	.	133	135	GGC	465	467	GGC	31;31;31	G;G;C	21;20;21	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	84	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	712	21.3	0	.	n	.	0	A197.	DEL	197	197	A	293	293	A	40	A	23	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1309	1311	GTC	16;19;19	G;T;C	10;12;12	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	1	SNP	p	D86N	0	.	.	256	258	GAC	415	417	GAC	26;26;27	G;A,G;C	16;15,1;18	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	1	SNP	p	S87R	1	.	.	259	261	CGT	418	420	CGT	27;27;27	C;G;T	19;17;18	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	1	SNP	p	R87W	0	.	.	259	261	CGT	418	420	CGT	27;27;27	C;G;T	19;17;18	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	1	SNP	p	R87I	0	.	.	259	261	CGT	418	420	CGT	27;27;27	C;G;T	19;17;18	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	370	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2761	25.7	1	SNP	p	S88P	0	.	.	262	264	TCC	421	423	TCC	26;26;26	T;C;C	18;18;19	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	306	parE	1986	1986	99.95	parE.l15.c17.ctg.1	3195	19.4	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1629	1631	TGC	24;24;24	T;G;C	14;13;14	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	306	parE	1986	1986	99.95	parE.l15.c17.ctg.1	3195	19.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1839	1841	GGC	25;25;25	G;G;C	16;16;16	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1287	1289	GCA	50;51;52	G;C;A	29;29;32	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1290	1292	ATC	54;54;54	A;T;C,T	33;31;32,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1302	1304	GTG	56;56;56	G;T;G	34;32;34	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1302	1304	GTG	56;56;56	G;T;G	34;32;34	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1806	1808	ACC	21;21;22	A;C;C	13;14;15	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1860	1862	GCG	27;27;27	G;C;G	15;16;14	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1860	1862	GCG	27;27;27	G;C;G	15;16;14	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1983	1985	GGC	20;20;22	G;G;C	14;13;14	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1992	1994	GGC	22;22;19	G;G;C	16;14;13	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	360	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2232	29.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2010	2012	TCG	20;19;19	T;C;G	13;12;11	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	822	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3012	47.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1534	1536	CCG	33;33;33	C;C;G	21;22;22	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	222	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1980	21.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	582	582	C	8	C	6	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	645	647	GAA	22;23;23	G;A;A	15;16;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	933	935	GAT	28;29;29	G;A;T	19;18;19	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1056	1058	TCA	37;37;37	T;C;A	22;23;23	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1185	1187	GTC	32;34;33	G;T;C	21;22;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1407	1409	ACT	37;40;40	A;C;T	21;25;26	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1515	1517	GCA	33;33;33	G;C;A	22;22;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	1	SNP	p	G120K	1	.	.	358	360	AAG	891	893	AAG	33;33;33	A;A;G	20;21;21	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	1	SNP	p	D121N	0	.	.	361	363	GAC	894	896	GAC	33;32;32	G;A;C	21;19;19	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	212	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1855	21.6	1	SNP	p	A121D	1	.	.	361	363	GAC	894	896	GAC	33;32;32	G;A;C	21;19;19	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	842	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4694	34.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1966	1968	AAT	40;40;40	A;A;T	26;26;27	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	88	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1234	14.2	1	SNP	p	V57M	1	.	.	169	171	ATG	530	532	ATG	24;24;24	A;T;G	16;18;18	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
